Contatti:
cell: +39 329 0364389
info@biomole.it
biomole@ALL RIGHT RESERVED 2019
TPMT-MAMAPCR real time
Quantification assay of Thiopurine Methyltransferase cod. BM-007
Principle of the test: Detect abnormal TPMT enzyme activity due to genetics
Technology: MAMA PCR real time
Gene Target: TPMT 2, 3B, 3C
Specimen: DNA
Results: Haplotype set
Reporting Units: Arbitrary Units (AU)
Number of tests: 25 tests BM-007
Kit storage: -20°C
Necessary equipment: 7500 Real Time PCR System
Status: Ready to use
TPMT-MAMAPCR real time cod. BM-007
Quantification assay of Thiopurine Methyltransferase
· TPMT-MAMAPCR real time Quantification complete kit 25 tests BM-007
Thiopurine drugs such as azathioprine (AZA), 6-mercaptopurine (6-MP), and 6-thioguanine (6-TG) are widely used in the treatment of acute lymphoblastic leukemia (ALL), autoimmune diseases, inflammatory bowel disease, and posttransplant organ rejection. Patients with abnormal thiopurine methyltransferase (TPMT) enzyme activity due to genetics and/or drug-drug interactions have an increased risk of toxicity when given thiopurines.
TPMT-MAMAPCR real time Quantification BM-007 is research use only (RUO) assay for the detection of allele variants TPMT*2, *3B, and *3C, found to be responsible of enzyme activity alteration.
Reference
1. Cheok MH, Lugthart S, Evans WE. Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol. 2006;46:317–353.
2. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine. Gut. 2003;52:140–142.
3. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-tosevere atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839– 846.
4. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharm Ther. 2004;20:593–599.